TipRanks
Go Ultimate55% OFF

Compare Sinopharm Group Co (X2S) vs. Competitors

0 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
DE:X2SSinopharm Group CoEUR 1.92EUR 5.92B6.30-10.40%Strong BuyUnlock the DE:X2S analyst price target with TipRanks PremiumDE:X2SUnlock the DE:X2S top-analyst price target with TipRanks Premium
HK:0673China Health GroupHKD 0.28HKD 360.66M-5.29-58.82%―Unlock the HK:0673 analyst price target with TipRanks PremiumDE:X2S vs HK:0673Unlock the HK:0673 top-analyst price target with TipRanks Premium
HK:2607Shanghai Pharmaceuticals Holding CoHKD 11.20HKD 65.80B12.13-5.72%Moderate BuyUnlock the HK:2607 analyst price target with TipRanks PremiumDE:X2S vs HK:2607Unlock the HK:2607 top-analyst price target with TipRanks Premium
HK:1931IVD Medical Holding LimitedHKD 0.34HKD 551.31M-6.20-94.30%―Unlock the HK:1931 analyst price target with TipRanks PremiumDE:X2S vs HK:1931Unlock the HK:1931 top-analyst price target with TipRanks Premium
HK:2192Medlive Technology Co., Ltd.HKD 6.48HKD 4.58B11.97-36.33%Moderate BuyUnlock the HK:2192 analyst price target with TipRanks PremiumDE:X2S vs HK:2192Unlock the HK:2192 top-analyst price target with TipRanks Premium
HK:2289Charmacy Pharmaceutical Co., Ltd. Class HHKD 5.49HKD 592.92M10.85-8.04%―Unlock the HK:2289 analyst price target with TipRanks PremiumDE:X2S vs HK:2289Unlock the HK:2289 top-analyst price target with TipRanks Premium

Performance Comparison

-100%-75%-50%-25%0%25%50%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
DE:X2SSinopharm Group Co1.92-0.26-12.08%
HK:0673China Health Group0.28-0.38-57.58%
HK:2607Shanghai Pharmaceuticals Holding Co11.20-0.06-0.56%
HK:1931IVD Medical Holding Limited0.34-5.74-94.41%
HK:2192Medlive Technology Co., Ltd.6.47-3.31-33.85%
HK:2289Charmacy Pharmaceutical Co., Ltd. Class H5.49-0.13-2.26%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts